Dementia and Alzheimer’s Flashcards

1
Q

what is the definition of dementia

A

Dementia
Chronic progressive mental disorder that adversely affects higher cortical functions including memory, thinking, orientation, comprehension, calculation, learning capacity, language and judgment.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is the definition of Alzheimer’s disease

A

Alzheimer’s disease
Most common form of dementia.
Degenerative cerebral disease with characteristic neuropathological and neurochemical features
Onset and development is slowly but steadily over several years
Progressive deterioration in cognition, function and behavior

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are the common symptoms of AD?

A

Cognitive
Memory loss
Failing intellect (inability to learn new skills)
Poor concentration
Language impairment
Disorientation/confusion

Non-cognitive
Depression
Delusion
Anxiety
Aggression
Sleep disturbances
Dis-inhibition

Disability
Difficulties with activities of daily living
Self-neglect
Incontinence and other physical disabilities

Symptoms of AD may be confused with:
-Vitamin deficiency
-Thyroid problems
-Infection
-Anxiety
-Brain Tumour
-Depression
-Diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is the pathology of AD?

A

Loosing brain tissues as it a neurogenerative disease
Ventricles are enlarged in Alzheimers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what are the proteins which are present in the brain when someone has AD?

A

Amyloid plaques and Neurofibrillary tangles

“scattered throughout the entire cortex……one found military foci that
were caused by the deposition of a peculiar substance” A. Alzheimer

*protein accumulation due to deposition)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what is the diagnosis of AD?

A

Symptoms & Memory assessment (Clinical criteria)

MRI and PET Scans for biomarkers (Neuropathological hallmarks)

Outcomes:
Memory tests can show problems in particular areas
CT and MRI scans may show brain shrinkage (atrophy)
PET scans may show areas of
Loss of function (fluoro­ deoxyglucose [FDG]­PET)
Presence of AD biomarkers (PET with amyloid-binding radiotracer or chemical marker of cerebrospinal fluid [CSF] amyloid and tau proteins)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what is mini mental state exam?
and clock drawing test

A

Individuals’ ability to recall certain things
Quick but blunt to diagnose dementia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what does MRI show?

A

Highlights atrophy in hippocampus and mesiotemporal lobe (MT)
Can detect pre-symptomatic changes
Non-invasive
Reproducible and quantitative read out.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what does fluorodeoxyglucose(FDG)-positron emission tomography (PET)
show?

A

Highlights deficits in parietal lobe (P) and posterior cingulate gyrus (PCG).
Links metabolic state to synaptic activity.
Open to errors from other metabolic changes.
Useful tool in differentiating dementia’s (e.g. AD vs FTD).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are the risk factors of AD?

A

40% cause-modifiable factors
60% - unknown

education
hearing loss
traumatic brain injury
hypertension
alcohol
obesity
smoking
depression
physcial activity etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what are the genes associated with AD?

A

Psen 1, pesen 2, app – early onset (prink – guaranteed to develop AD)
Apoe + trem 2 – increases risk off – late onset

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what are the 2 types of AD?

A

early onset
late onset

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

APP processing

A

APP- transmembrane protein
Normal healthy people – APP is cleaved by 2 diff enymes (alpha) – into segments
Develop AD- enzyme different which causes cleaves – beta – production of amyloid fragments – forming the plaques

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is the amyloid cascade hypothesis

A

initiated by
increase in amyloid B production
decreases amyloid B Degradation

increase Amyloid B accumulation
Amyloid B oligomerisation and deposition
Inflammatory response
Synapse loss
Oxidative stress
Ca2+ overload and neuronal death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is the Current pharmacological options AD

A

Anti-amyloid monoclonal antibody [aducanumab]
Cholinergic signalling
Glutamatergic signalling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Cholinergic Synapse

A

Treating symptoms
Blocking ache -> eleveated levels of acetylcholine

17
Q

Modulating neurotransmission
what are examples of Acetylcholinesterase Inhibitors
effects
side effects

A

Donepezil
Galantamine
Rivastigmine

Effects:
Enhance cholinergic transmission and improve cognitive functions
Therapeutic effectiveness decreases with increasing neuronal damage
Does not prevent progression of disease!
Benefit assessed by repeating the cognitive assessment after 3 months treatment.
Discontinue treatment if patient does not respond to therapy!
Only a subset of patients respond

High doses have side effects e.g., nausea, vomiting, diarrhoea

18
Q

Glutamatergic transmission

A

AD- too much glutamate
Slow it down
NMDAR – dampen down the signalling from this receptor

19
Q

N-methyl D-aspartate antagonism
moa
effects
interactions

A

Memantine- non-competitive antagonist at NMDA receptors.

Effects:
Improves cognitive functions
Effects evident at late stages of disease
Role in early stage of AD unclear…
Not certain if it prevents progression of disease…

Possible drug interactions e.g., antipsychotic (see non-cognitive changes and treatments!), anticoagulant (warfarin), analgesic and muscle relaxant.

20
Q

what are the treatments for AD according to NICE guidelines

A

Donepezil, Galantamine and Rivastigmine recommended for managing:
mild
moderate Alzheimer’s disease

Memantine is now recommended as an option for managing:
moderate Alzheimer’s disease for people who cannot take AChE inhibitors
severe Alzheimer’s disease
In combination? Not currently recommended

21
Q

what are Novel strategies for treating dementia

A

Modulating neurotransmission
Amyloid based therapies
Tau based therapies
Mitochondrial targeted therapy
Anti-inflammatory therapy
Drug repurposing

22
Q

PHARMACOLOGICAL INTERVENTION
BEHAVIOUR That challenges

Antipsychotics
- Patients with mild-to moderate non-cognitive symptoms should not be prescribed antipsychotic drugs
- Patients with psychosis and/or agitated behaviour causing significant distress may be offered treatment with an antipsychotic

Sedatives
For challenging behaviour: violence, aggression, severe agitation: i.m. Lorazepam, Haloperidol or Olanzapine

EMOTIONAL disorders

Antidepressants
People with dementia who also have major depressive disorder should be offered antidepressant medication

Avoid certain TCA and MAOI as they have anticholinergic properties

A
23
Q

Clinical trials/approvals

2022: lecanemab (Eisai)
2021: aducanumab (Biogen)

  • CONTRAVERSIAL

Aducanumab is a monoclonal antibody that removes amyloid plaques.
The central controversy is whether the amyloid clearance protects
patients from cognitive and functional decline

A